Person: Dr Alan Bernstein

Marc Lepage

Marc Lepage is returning to Canada to take the helm at Genome Quebec after spending seven years in the US. Lepage replaces interim president and CEO Denis Bilodeau, who stepped in following the departure of Jean-Marc Proulx last year. Lepage has had a long career in the public service including stints at the Medical Research…

Dr Alan Bernstein

Dr Alan Bernstein has been appointed president and CEO of the prestigious Canadian Institute for Advanced Research (CIFAR), effective May 1st. Bernstein replaces longstanding CIFAR head Chaviva Hosek, who announced more than one year ago that she was stepping down after 11 years (R$, December 13/10). Bernstein recently completed a five-year term as executive director…

Dr. Alan Bernstein

CIHR president comments on panel report
Dr. Alan Bernstein

Earlier this year, the Canadian Institutes of Health Research (CIHR), as required by its legislation and its commitment to accountability, underwent an open international review of our first five years of operation.

Dr. Alan Bernstein

Making the case for health research
Dr. Alan Bernstein

Accountability is the new buzzword in Ottawa. Today, like all investors, Canadians want evidence that their funds are being invested wisely and their investments are producing results.

Karimah Es Sabar

Karimah Es Sabar has been appointed executive director of BC Biotech, an association representing the province’s biotechnology industry. Es Sabar was most recently VP and COO of Medsurge Medical Inc. Prior to that, she was founder and managing director of SAL Healthcare Ltd, a marketing, distribution and consulting firm in Nairobi Kenya. Es Sabar holds…

Dr André Musy

Dr André Musy has been appointed DG of Ouranos, the research institute of Hydro-Québec. Musy comes to Ouranos from the École Polytechnique Fédérale de Lausanne (EPFL). His experience in hydrology, the environment and land and water use is well suited to Ouranos’ two-pronged research program of climate science/hydrology and impacts and adaptation strategies. Musy holds…

Dr Trevor Hawkins

Dr Trevor Hawkins has been appointed to the newly created position of chief science and technology officer at MDS Inc. Hawkins joins MDS during a period of transition in the executive suite (see below). He was previously president of the molecular diagnostics business unit at GE Healthcare and senior VP development and new business initiatives…

Stephen DeFalco

Stephen DeFalco has been appointed COO of MDS Inc and will become president and CEO when he replaces retiring John Rogers at the end of 2005. Defalco is chair and CEO of US Genomics, a firm he founded in 2003. Prior to that he was president of PerkinElmer Instruments and senior VP of PerkinElmer Inc.…

Gregory McKee

Gregory McKee has been appointed president and CEO of Victoria-based Stressgen Biotechnologies Corp, replacing Dan Korpolinski. The move comes after Stressgen withdrew its preliminary prospectus for a common share offering and a decision to sell its bioreagents business to a US firm (see New Briefs). Prior to his appointment, McKee was Stressgen’s chief financial officer…